Intravenous immunoglobulin treatment abrogates transplacental autoantibody transfer in a murine pemphigus model Sachiko Ono, MD, PhD, Gyohei Egawa, MD, PhD, Tetsuya Honda, MD, PhD, Kenji Kabashima, MD, PhD Journal of Allergy and Clinical Immunology Volume 141, Issue 6, Pages 2273-2276.e1 (June 2018) DOI: 10.1016/j.jaci.2017.12.985 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Anti–Dsg3 antibody deposition in the fetal skin with or without IVIG treatment. A, Gating strategy of fetal keratinocytes (upper panels) and IgG1 quantification (lower panels) on keratinocytes after the injection of PBS or AK18 to pregnant mice. B, IgG1-MFI of fetuses of pregnant mice treated with IVIG or PBS. *P < .05. C, IgG1-MFI of the ear keratinocytes of adult mice treated with IVIG at 1.0 g/kg/d or PBS. FSC-A, Forward scatter-area; NS, not significant; SSC-A, side scatter-area. *P < .05. Journal of Allergy and Clinical Immunology 2018 141, 2273-2276.e1DOI: (10.1016/j.jaci.2017.12.985) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Efficacy of IVIG treatment on pemphigus manifestations. A, Hair loss in pregnant mice injected with AK23 and PBS or IVIG. B, Hematoxylin and eosin staining of the fetal back skin. Black arrows indicate intraepidermal blistering. Bars = 50 μm. C, Immunohistochemical staining of the fetal back skin (left panels) or the yolk sac placentas (right panels) of pregnant mice. Bars = 50 μm. Yellow arrows indicate epidermal AK23 deposition, green arrows indicate intrinsic IgG deposition, and red arrows indicate deposition of IVIG. D, Serum AK23 titers in fetuses. *P < .05. Journal of Allergy and Clinical Immunology 2018 141, 2273-2276.e1DOI: (10.1016/j.jaci.2017.12.985) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions